Glaxo Reaches $229 Million Settlement With 8 States on Avandia

GlaxoSmithKline Plc (GSK) has reached a $229 million settlement in principle with eight U.S. states to resolve lawsuits relating to the development and marketing of its Avandia diabetes drug, and a separate action from Louisiana for other products.

The amount is within existing provisions set aside for legal matters, the London-based company said in a statement yesterday.

Glaxo said last year it agreed to pay $3 billion to settle federal and state government claims that it illegally promoted prescription drugs and failed to report clinical data on Avandia, once the world’s best-selling diabetes pill. The drug, which was withdrawn from the European market in 2010, is governed by a strict program in the U.S. that limits its use to patients who understand the risks and have no alternatives.

The $3 billion settlement was the largest-ever in a health-care fraud case in the U.S.

At least 41 whistle-blower complaints against pharmaceutical companies have been filed in U.S. federal fraud cases that contained allegations of improper marketing between 1996 and 2010, leading to $7.9 billion in settlements, according to Aaron Kesselheim of the Harvard School of Public Health.

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editor responsible for this story: Phil Serafino at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.